Drug name
GS-4182
Developer(s)
Drug information
Not provided
GS-4182
investigational
Small molecule
GS-4182 is an investigational lenacapavir prodrug with improved bioavailability and potential for oral weekly administration. The chemical structure of GS-4182 is not yet available in the public domain. GS-4182 is studied in combination with GS-1720, a new oral INSTI. Phase II/III WONDERS trials are currently underway using the GS-4182+GS-1720 combination. If successful, a weekly oral HIV treatment could provide a valuable alternative for PLHIV.
GS-4182 is currently in clinical development and not yet approved in any jurisdiction.
GS-4182 is currently in clinical development and not yet approved in any jurisdiction.
Therapeutic area(s)
- HIV
- Treatment
Administration route
Oral
Associated long-acting platforms
Oral solid form
Use of drug
- Self-administered
Not provided
Dosage
300mg is the investigated dose
once a week oral dosing with GS-1720 is the investigated schedule
600mg is the investigated loading dose (2 tablets)
In the phase 2/3 study (NCT06613685), participants will receive a 1-day loading dose of GS-1720 (1300 mg) and GS-4182 (600 mg) on Day 1.Thereafter, participants will take weekly doses of single agent GS-1720 (650 mg) and GS-4182 (300 mg) co-administered for at least 48 weeks.
Not provided
Not provided
Associated technologies
Not provided
Comment & Information
Developer(s)
Drug structure
Scale-up and manufacturing prospects
Detailed manufacturing information is not currently available for this compound.
Detailed manufacturing information is not currently available for this compound.
Detailed manufacturing information is not currently available for this compound.
Detailed manufacturing information is not currently available for this compound.
Excipients
Not provided
Not provided
Not provided
Delivery device(s)
Not provided
There are either no relevant patents or these were not yet submitted to LAPaL
Publications
There are no publication
Additional documents
No documents were uploaded
Useful links
There are no additional links
Collaborate for development
Consider on a case by case basis, collaborating on developing long acting products with potential significant public health impact, especially for low- and middle-income countries (LMICs), utilising the referred to long-acting technology
Share technical information for match-making assessment
Provide necessary technical information to a potential partner, under confidentiality agreement, to enable preliminary assessment of whether specific medicines of public health importance in LMICs might be compatible with the referred to long-acting technology to achieve a public health benefit
Work with MPP to expand access in LMICs
In the event that a product using the referred to long-acting technology is successfully developed, the technology IP holder(s) will work with the Medicines Patent Pool towards putting in place the most appropriate strategy for timely and affordable access in low and middle-income countries, including through licensing